MedTrace Logo

Seroepidemiological Investigation of Coronavirus 2019 (COVID-19) Infection in Gabon

NCT05065632 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3455

Last updated 2023-06-22

No results posted yet for this study

Summary

Gabon is the 3rd country most affected by COVID-19 behind Cameroon and Democratic Republic of Congo in Central Africa, with 8860 cases and 54 deaths in critically ill patients, since the first confirmed case of COVID-19 on the 10th of March 2020 (https://africacdc.org/covid-19/). Most of the individuals infected by SARS-CoV-2 are asymptomatic and they represent a major source of viral spread. To date, African countries have been less affected by deaths caused by the Covid-19 pandemic compared to other countries. It is currently unknown why Africa has avoided more deaths and appears to not simply be due to a lack of testing, since the overall death rate has not increased. Better quality data on seroprevalence in different African regions and proven explanations of the differences between Africa and other continents, are urgently needed. The aim of this study is to learn about the proportion of people after a first pic of transmission, who have been exposed to COVID-19 in Gabon by testing for plasma antibodies to the SARS-CoV-2 virus.

The overall goal of this study is to examine the trend of specific anti-SARS-CoV-2 antibodies in Gabonese population.

Conditions

  • Laboratory Confirmed SARS-CoV-2 Infection Without Symptoms

Interventions

DIAGNOSTIC_TEST

Wantai kit Elisa

to mesure antibodies against SARSCov-2 recombinant antigen

Sponsors & Collaborators

  • Prof. Ayola Akim ADEGNIKA

    lead OTHER

Principal Investigators

  • Ayola Akim A ADEGNIKA, PhD · Centre de Recherche Médicale de Lambaréné

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • Gabon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065632 on ClinicalTrials.gov